Arezou Ghazani
Director of Clinical Genomics, Brigham Genomic Medicine,
Brigham and Women's Hospital/Harvard Medical School
Dr. Ghazani is a board-certified medical geneticist (ABMGG) and clinical scientist with 10 years of experience in clinical genomics and precision oncology and is well-versed in CLIA/CAP genetic testing regulations across academia and industry.
Her leadership role in clinical genomics involves the development and implementation of novel platforms and methods for the clinical interpretation of the genome, and investigation of complex genome structure. Dr. Ghazani's clinical activities include the interpretation of clinically actionable genomic targets in cancer and constitutional rare disorders. She is also the Founder and Director of several large-scale and multi-institutional genome programs at Brigham and Women's Hospital, including CroSeq Pediatrics and INT²GRATE Oncology.
Dr. Ghazani's research activities are focused on using an integrated approach in the evaluation of somatic (tumor) and germline (constitutional) genomic data to aid interpretation of germline variants and assessment of their clinical utility in cancer. Her passion for bridging scientific advances with current clinical needs led to the development of INT²GRATE. Implemented in a multi-institutional cancer coalition, INT²GRATE incorporates tumor-derived signature profiles and clinical genetic information to identify clinically actionable germline alterations in cancer patients.
Teaching has been a key part of Dr. Ghazani's passion. Since 2012, she has been directing and teaching Introduction to Genomics, at Harvard University. This course provides an overview of genome architecture, comparative genomics, regulatory mechanisms, and social and ethical impacts resulting from advances in genomic studies. In 2021, Dr. Ghazani was invited to direct and teach Precision Medicine in Genomics, at Harvard University; the course covers advanced topics in the clinical genomic practice.
Outside academia, Dr. Ghazani leads Next Generation Sequencing (NGS) inspection teams through the College of American Pathologists (CAP). As a lead NGS CAP inspector, she has been evaluating compliance with regulatory requirements of CLIA-certified laboratories in the U.S. and Canada since 2012.
Her leadership role in clinical genomics involves the development and implementation of novel platforms and methods for the clinical interpretation of the genome, and investigation of complex genome structure. Dr. Ghazani's clinical activities include the interpretation of clinically actionable genomic targets in cancer and constitutional rare disorders. She is also the Founder and Director of several large-scale and multi-institutional genome programs at Brigham and Women's Hospital, including CroSeq Pediatrics and INT²GRATE Oncology.
Dr. Ghazani's research activities are focused on using an integrated approach in the evaluation of somatic (tumor) and germline (constitutional) genomic data to aid interpretation of germline variants and assessment of their clinical utility in cancer. Her passion for bridging scientific advances with current clinical needs led to the development of INT²GRATE. Implemented in a multi-institutional cancer coalition, INT²GRATE incorporates tumor-derived signature profiles and clinical genetic information to identify clinically actionable germline alterations in cancer patients.
Teaching has been a key part of Dr. Ghazani's passion. Since 2012, she has been directing and teaching Introduction to Genomics, at Harvard University. This course provides an overview of genome architecture, comparative genomics, regulatory mechanisms, and social and ethical impacts resulting from advances in genomic studies. In 2021, Dr. Ghazani was invited to direct and teach Precision Medicine in Genomics, at Harvard University; the course covers advanced topics in the clinical genomic practice.
Outside academia, Dr. Ghazani leads Next Generation Sequencing (NGS) inspection teams through the College of American Pathologists (CAP). As a lead NGS CAP inspector, she has been evaluating compliance with regulatory requirements of CLIA-certified laboratories in the U.S. and Canada since 2012.
Sessions
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
)
)
)
)
){kind=logo}
){kind=logo}
){kind=logo}